Related references
Note: Only part of the references are listed.Circulating Endothelial Cells A New Candidate Biomarker of Irreversible Pulmonary Hypertension Secondary to Congenital Heart Disease
David M. Smadja et al.
CIRCULATION (2009)
Guidelines for the diagnosis and treatment of pulmonary hypertension
N. Galie et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension
Kewal Asosingh et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat
Frank Kramer et al.
BIOMARKERS (2008)
Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension
Jay Suntharalingam et al.
CHEST (2008)
Prostacyclin therapies for the treatment of pulmonary arterial hypertension
M. Gomberg-Maitland et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Biomarkers in pulmonary hypertension
G. Warwick et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Endothelin receptor antagonists in pulmonary arterial hypertension
J. Dupuis et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices
Hendrik Milting et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2008)
Emerging therapies for pulmonary arterial hypertension
Omar Ali et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Management of pulmonary arterial hypertension with a focus on combination therapies
Raymond L. Benza et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2007)
Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension
M. M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Sildenafil treatment for portopulmonary hypertension
F. Reichenberger et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension
Anna Fijalkowska et al.
CHEST (2006)
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
MM Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Inhaled lloprost reverses vascular remodeling in chronic experimental pulmonary hypertension
RT Schermuly et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury
M Tamaoki et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy
RE Stroud et al.
JOURNAL OF CARDIAC FAILURE (2005)
Now predictors of outcome in idiopathic pulmonary arterial hypertension
SM Kawut et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Clinical significance of brain natriuretic peptide in primary pulmonary hypertension
HH Leuchte et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Clinical classification of pulmonary hypertension
G Simonneau et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression
V Polyakova et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Diagnostic and prognostic usefulness of natriuretic peptides in emergency department patients with dyspnea
SP Collins et al.
ANNALS OF EMERGENCY MEDICINE (2003)
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension -: Prognostic factors and survival
O Sitbon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Assessment of survival in patients with primary pulmonary hypertension importance of cardiopulmonary exercise testing
R Wensel et al.
CIRCULATION (2002)
Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction
K Imanaka-Yoshida et al.
LABORATORY INVESTIGATION (2001)
Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease
KN Cowan et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
